Literature DB >> 32785651

Ultrasound Characterization of Disordered Antral Follicle Development in Women with Polycystic Ovary Syndrome.

Brittany Y Jarrett1, Heidi Vanden Brink1, Alexis L Oldfield1, Marla E Lujan1.   

Abstract

CONTEXT: The mechanism of oligo-anovulation in polycystic ovary syndrome (PCOS) is unknown.
OBJECTIVES: To evaluate follicular and endocrine characteristics of anovulatory and sporadic ovulatory cycles in women with PCOS.
DESIGN: Prospective, longitudinal study.
SETTING: Academic clinical research unit. PARTICIPANTS: 26 reproductive-aged women (18-38 years) with PCOS, observed during natural anovulatory (PCOS-Anov; n = 12) and sporadic ovulatory cycles (PCOS-Ov; n = 14), and 12 controls.
INTERVENTIONS: Transvaginal ultrasonography and venipuncture were performed every other day for 4 to 6 weeks in women with PCOS or at 1 interovulatory interval in control subjects. MAIN OUTCOME MEASURES: Follicle number and diameter (ie, ≥2 mm) were quantified at each visit. Individual growth profiles were assessed for all follicles that grew to ≥7 mm. Blood samples were assayed for follicle-stimulating hormone, luteinizing hormone, estradiol, and progesterone.
RESULTS: Follicular excess, or heightened follicle number versus controls, was observed across anovulatory and sporadic ovulatory cycles in PCOS. In PCOS-Anov, follicles emerged cyclically in some women (6/12; 50%) and continuously in others (6/12; 50%), then grew to a mean maximum diameter of 7.2 mm and regressed within 4.7 days. In PCOS-Ov, follicles mostly emerged cyclically as part of a cohort and dominant follicles showed normal growth to ovulation-albeit mean and maximum luteal progesterone concentrations were significantly lower versus controls.
CONCLUSIONS: Follicle growth and regression were detected on ultrasonography amidst perpetual follicular excess in PCOS. Documentation of continuous follicle recruitment and turnover, the absence of persistence, and altered luteal progesterone following sporadic ovulation, provide formative data on antral follicle development in PCOS. © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  anovulation; ovarian follicle; polycystic ovary syndrome; ultrasonography

Mesh:

Substances:

Year:  2020        PMID: 32785651      PMCID: PMC7473602          DOI: 10.1210/clinem/dgaa515

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  42 in total

Review 1.  Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion.

Authors:  D A Ehrmann; R B Barnes; R L Rosenfield
Journal:  Endocr Rev       Date:  1995-06       Impact factor: 19.871

Review 2.  A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome.

Authors:  C M Boomsma; M J C Eijkemans; E G Hughes; G H A Visser; B C J M Fauser; N S Macklon
Journal:  Hum Reprod Update       Date:  2006-08-04       Impact factor: 15.610

3.  Variability in the phases of the menstrual cycle.

Authors:  Richard J Fehring; Mary Schneider; Kathleen Raviele
Journal:  J Obstet Gynecol Neonatal Nurs       Date:  2006 May-Jun

Review 4.  Follicle dynamics and anovulation in polycystic ovary syndrome.

Authors:  Stephen Franks; Jaroslav Stark; Kate Hardy
Journal:  Hum Reprod Update       Date:  2008-05-22       Impact factor: 15.610

5.  Timing of oocyte maturation and egg collection during controlled ovarian stimulation: a randomized controlled trial evaluating manual and automated measurements of follicle diameter.

Authors:  Nick Raine-Fenning; Shilpa Deb; Kannamannadiar Jayaprakasan; Jeanette Clewes; James Hopkisson; Bruce Campbell
Journal:  Fertil Steril       Date:  2009-04-01       Impact factor: 7.329

6.  Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society.

Authors:  Didier Dewailly; Marla E Lujan; Enrico Carmina; Marcelle I Cedars; Joop Laven; Robert J Norman; Héctor F Escobar-Morreale
Journal:  Hum Reprod Update       Date:  2013-12-16       Impact factor: 15.610

7.  Pulsatile luteinizing hormone amplitude and progesterone metabolite excretion are reduced in obese women.

Authors:  Akas Jain; Alex J Polotsky; Dana Rochester; Sarah L Berga; Tammy Loucks; Gohar Zeitlian; Karen Gibbs; Hanah N Polotsky; Sophia Feng; Barbara Isaac; Nanette Santoro
Journal:  J Clin Endocrinol Metab       Date:  2007-04-17       Impact factor: 5.958

Review 8.  The effect of obesity on polycystic ovary syndrome: a systematic review and meta-analysis.

Authors:  S S Lim; R J Norman; M J Davies; L J Moran
Journal:  Obes Rev       Date:  2012-10-31       Impact factor: 9.213

9.  Premature response to luteinizing hormone of granulosa cells from anovulatory women with polycystic ovary syndrome: relevance to mechanism of anovulation.

Authors:  D S Willis; H Watson; H D Mason; R Galea; M Brincat; S Franks
Journal:  J Clin Endocrinol Metab       Date:  1998-11       Impact factor: 5.958

10.  Growth rates of ovarian follicles during natural menstrual cycles, oral contraception cycles, and ovarian stimulation cycles.

Authors:  Angela R Baerwald; Randy A Walker; Roger A Pierson
Journal:  Fertil Steril       Date:  2008-02-04       Impact factor: 7.329

View more
  3 in total

1.  Exosomal miR-143-3p derived from follicular fluid promotes granulosa cell apoptosis by targeting BMPR1A in polycystic ovary syndrome.

Authors:  Yuanyuan Zhao; Shuhong Pan; Yunying Li; Xiaohua Wu
Journal:  Sci Rep       Date:  2022-03-14       Impact factor: 4.996

2.  Where are we in understanding the natural history of polycystic ovary syndrome? A systematic review of longitudinal cohort studies.

Authors:  Sylvia Kiconco; Chau Thien Tay; Kate Louise Rassie; Ricardo Azziz; Helena J Teede; Anju E Joham
Journal:  Hum Reprod       Date:  2022-05-30       Impact factor: 6.353

3.  A Mechanism for Ovulation Number Control.

Authors:  Michal Shilo; Avi Mayo; Uri Alon
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-14       Impact factor: 6.055

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.